MDS Nordion Enters Collaboration Agreement with Avid Radiopharmaceuticals on Imaging Compounds for Alzheimer's Disease
04 Aprile 2007 - 3:00PM
PR Newswire (US)
New molecular imaging agents may allow early detection of the
plaque associated with Alzheimer's disease OTTAWA, April 4
/PRNewswire-FirstCall/ -- MDS Nordion, a leading global provider of
medical isotopes and radiopharmaceuticals used in molecular
medicine, has entered into a collaboration agreement with Avid
Radiopharmaceuticals Inc. to support clinical studies for Avid's
novel radiopharmaceuticals designed to diagnose and monitor
Alzheimer's disease. These trials will use advanced molecular
imaging known as single photon emission computed tomography
(SPECT). Under the terms of the agreement, MDS Nordion will
radiolabel Avid's proprietary compounds for use in proof-of-concept
clinical trials for SPECT imaging of Alzheimer's disease. Avid is a
pioneer in the development of radiopharmaceuticals for imaging
Alzheimer's disease pathology. Increasingly, molecular imaging is
being used as a biomarker tool to guide the development of new
therapeutics. Avid's lead product candidates are being developed to
identify amyloid protein plaques, which are thought to accumulate
in the brain before the onset of clinical symptoms of the disease.
Avid's compounds may enable the earlier diagnosis of Alzheimer's
disease and also allow researchers to better evaluate therapeutic
drug candidates for the prevention or reversal of amyloid plaque
build-up in the brain. According to the Alzheimer's Association,
there are approximately 5 million people in the United States who
suffer from Alzheimer's disease. As the population ages that number
is expected to grow significantly. Meanwhile, the costs associated
with the disease are considerable. The Alzheimer's Association
estimates that the direct and indirect costs for treatment and care
of Alzheimer's patients in the United States alone is US $148
billion annually. "This partnership with Avid provides an exciting
opportunity to develop a new molecular imaging agent that can
assist researchers to identify a more effective therapy for
patients with this debilitating disease," said Steve West,
President of MDS Nordion. "MDS Nordion is using its proprietary
technologies to work to develop these important compounds with our
pharmaceutical and bio-pharmaceutical partners." MDS Nordion has an
established global track-record in radiopharmaceutical formulation,
production and process development. It provides integrated services
that support the discovery, development and production of molecular
imaging agents and radiopharmaceuticals. With GMP facilities in
Ottawa and Vancouver, Canada, and Fleurus, Belgium, MDS Nordion can
accommodate a variety of development, production and supply
requirements. "As a world leader in molecular medicine with
extensive experience and expertise in the development and
production of radiopharmaceuticals, it was a natural choice for us
to work with MDS Nordion on our molecular imaging agents for the
early and accurate diagnosis of Alzheimer's disease," said Alan
Carpenter, Vice President of Business Development at Avid. About
Avid Avid Radiopharmaceuticals, Inc. is a product-focused molecular
imaging company which is developing novel diagnostic imaging agents
to enable the earlier diagnosis, treatment selection and
therapeutic monitoring of major medical disorders. The company is a
pioneer in the development of molecular imaging agents for
Alzheimer's disease and other neurodegenerative diseases. Avid's
technology can be used with a variety of imaging techniques such as
positron emission tomography (PET) and single photon computed
tomography (SPECT) and is currently being tested in a number of
initial human studies. For more information, visit
http://www.avidrp.com/. About MDS Nordion MDS Nordion
(http://www.mdsnordion.com/) is a world leader in medical isotopes,
radiation and related technologies. It is a division of MDS Inc.
(TSX:MDS)(NYSE:MDZ). MDS Inc. is a global life sciences company
that provides market-leading products and services that our
customers need for the development of drugs and diagnosis and
treatment of disease. We are a leading global provider of
pharmaceutical contract research, medical isotopes for molecular
imaging, radiotherapeutics, and analytical instruments. MDS Inc.
has more than 6,200 highly skilled people in 28 countries. Find out
more at http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24
hours a day. DATASOURCE: MDS Nordion CONTACT: Media Inquiries,
Tamra Benjamin, Director, Marketing Communications, MDS Nordion,
(613) 592-3400 x1022, ; Investor Inquiries, Sharon Mathers, Senior
Vice-President, Investor Relations and External Communications,
(416) 675-6777 ext. 34721,
Copyright
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Mds (Borsa di New York (NYSE)): 0 articoli recenti
Più Mds Articoli Notizie